title: Urinary side effects and complications after permanent prostate brachytherapy: the MD Anderson Cancer Center experience.
abstract: OBJECTIVE
  To evaluate acute and long-term urinary morbidity after permanent prostate brachytherapy at a single tertiary care center. To minimize the risk of long-term urinary morbidity, it is important for clinicians to be able to distinguish acute urinary side effects after prostate brachytherapy from longer-term treatment-related urinary complications.
  
  
  METHODS
  The medical records of 351 consecutive patients who underwent prostate brachytherapy at the MD Anderson Cancer Center between 1998 and 2006 were analyzed. To evaluate the short-term urinary side effects, the Expanded Prostate Cancer Index Composite questionnaire was administered at baseline and at 1, 4, 8, and 12 months. Long-term urinary complications were scored using a modified Radiation Therapy Oncology Group scale.
  
  
  RESULTS
  All 4 urinary subdomain scores evaluating acute urinary side effects after treatment (bother, function, incontinence, and irritation or obstruction) had returned to baseline levels by 8 months after implantation. At 5 years, the cumulative risks of late urinary complications by grade were 8.6% for grade 1 complications, 6.5% for grade 2, 1.7% for grade 3%, and 0.5% for grade 4. The most common grade 2 late urinary complications were urethral stricture (4 patients), incontinence requiring daily pads (3 patients), and intermittent hematuria (3 patients). Grade 3 complications were urinary retention requiring self-catheterization (2 patients) and severe frequency with dysuria (2 patients). The only grade 4 event was severe hemorrhagic cystitis.
  
  
  CONCLUSIONS
  Short-term urinary side effects after prostate brachytherapy are common, follow a predictable course, and typically resolve within 1 year. Conservative management of short-term urinary side effects is recommended to minimize the risk of long-term urinary complications.
authors: Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
authors: John F
authors: JF
authors: Anderson
authors: David A
authors: DA
authors: Swanson
authors: Lawrence B
authors: LB
authors: Levy
authors: Deborah A
authors: DA
authors: Kuban
authors: Andrew K
authors: AK
authors: Lee
authors: Rajat
authors: R
authors: Kudchadker
authors: Jack
authors: J
authors: Phan
authors: Teresa
authors: T
authors: Bruno
authors: Steven J
authors: SJ
authors: Frank
mesh_terms: D000208:Acute Disease; D001918:Brachytherapy / Q000009:adverse effects*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D012189:Retrospective Studies; D013997:Time Factors; D014555:Urination Disorders / Q000453:epidemiology / Q000209:etiology*